Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Price analytics
Returns
1 day
0.0%
1 week
-0.5%
1 month
-7.5%
3 months
-12.1%
6 months
-35.4%
1 year
-59.1%
3 years
91.8%
Risk
Volatility (1y ann.)
80.8%
Beta vs ASX 200
2.22
Sharpe (1y)
-0.76
VaR 95% (1-day)
-7.1%
Max drawdown (1y)
-68.2%
Off 1-year high
-63.2%
Technicals
RSI(14)
46
vs 50DMA
-10.6%
vs 200DMA
-25.4%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value72.4
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
53
Price / Sales
0
Growth25.4
Revenue growth (1y)
25
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum1.6
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
7
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).